Evidence map›Paper›PMID 38374343›Full record

SynthesisNature medicine2024

A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk.

Marc Ferrell, Zeneng Wang, James T Anderson, Xinmin S Li, Marco Witkowski, Joseph A DiDonato, James R Hilser, Jaana A Hartiala, Arash Haghikia, Tomas Cajka and 9 more

Erratum issuedOpen access · greenAbstract readMeta-Analysis
In one paragraph

Synthesis in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 71 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
27.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Nutrition Information Briefs - Niacin.Advances in nutrition (Bethesda, Md.) · 2026
    Article
  11. Skin Cancer Prevention and Antiaging: Role of Nicotinamide.International journal of molecular sciences · 2026
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 3 countries.

Marc FerrellDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Zeneng WangDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-6455-8228
James T AndersonDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Xinmin S LiDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0003-4946-4271
Marco WitkowskiDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-6952-5038
Joseph A DiDonatoDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
James R HilserDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Jaana A HartialaDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0003-4883-9318
Arash HaghikiaDepartment of Cardiology, Angiology and Intensive Care, Deutsches Herzzentrum der Charité, Campus Benjamin Franklin, Berlin, Germany.ORCID 0000-0002-5646-3237
Tomas CajkaWest Coast Metabolomics Center, University of California, Davis, Davis, CA, USA.ORCID 0000-0002-9728-3355
Oliver FiehnWest Coast Metabolomics Center, University of California, Davis, Davis, CA, USA.ORCID 0000-0002-6261-8928
Naseer SangwanDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-2407-769X
Ilja DemuthDepartment of Endocrinology and Metabolism, Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-4340-2523
Maximilian KönigDepartment of Endocrinology and Metabolism, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Elisabeth Steinhagen-ThiessenDepartment of Endocrinology and Metabolism, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Ulf LandmesserDepartment of Cardiology, Angiology and Intensive Care, Deutsches Herzzentrum der Charité, Campus Benjamin Franklin, Berlin, Germany.ORCID 0000-0002-0214-3203
W H Wilson TangDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-8335-735X
Hooman AllayeeDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0002-2384-5239
Stanley L HazenDepartment of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. hazens@ccf.org.ORCID 0000-0001-7124-6639
Cleveland Clinic Lerner College of Medicine · USUniversity of Southern California · USCharité - Universitätsmedizin Berlin · DECleveland Clinic · USHumboldt-Universität zu Berlin · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DECzech Academy of Sciences · CZUniversity of California, Davis · US

Funding

Translational Research Support CoreP30ES007048 · NIEHS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROB S MCCONNELL · 1996 to 2026
$46.4M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
Project 3: Microbiota generated aryl sulfates and secondary bile acids in cardiometabolic diseaseP01HL147823 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI Stanley L Hazen · 2019 to 2026
$17.0M
Gut Flora Metabolism of Dietary Phosphatidylcholine and CVDR01HL103866 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI HAZEN, STANLEY L · 2010 to 2023
$10.8M
The impact of estrogen receptor alpha on cardiomyocellular metabolism and healthU54HL170326 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Hooman Allayee · 2023 to 2026
$7.5M
Role of Glycine Metabolism in Cardiovascular DiseaseR01HL133169 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ALLAYEE, HOOMAN · 2017 to 2020
$3.3M
Biological Mechanisms through which TMAO Promotes AtherosclerosisR01HL148110 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ALLAYEE, HOOMAN, SHIH, DIANA MOUHAN · 2020 to 2023
$2.5M
Nutrition, terminal NAD metabolites and cardiovascular diseaseR01HL169290 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI Stanley L Hazen · 2024 to 2026
$2.3M
Genetic Predisposition to Myocardial Infarction in Patients with Coronary Artery DiseaseR01HL168493 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Hooman Allayee · 2024 to 2026
$2.2M
CWRU- Cardiovascular Research Training ProgramT32HL134622 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI JAIN, MUKESH KUMAR, PROWELLER, AARON · 2017 to 2021
$1.9M
NHLBI NIH HHS P01 HL147823NHLBI NIH HHS R01 HL103866NHLBI NIH HHS R01 HL133169NHLBI NIH HHS R01 HL148110NHLBI NIH HHS R01 HL168493NHLBI NIH HHS R01 HL169290NHLBI NIH HHS T32 HL134622NHLBI NIH HHS U54 HL170326NIEHS NIH HHS P30 ES007048NIGMS NIH HHS T32 GM007250
6 · The paper itself

Abstract

Despite intensive preventive cardiovascular disease (CVD) efforts, substantial residual CVD risk remains even for individuals receiving all guideline-recommended interventions. Niacin is an essential micronutrient fortified in food staples, but its role in CVD is not well understood. In this study, untargeted metabolomics analysis of fasting plasma from stable cardiac patients in a prospective discovery cohort (n = 1,162 total, n = 422 females) suggested that niacin metabolism was associated with incident major adverse cardiovascular events (MACE). Serum levels of the terminal metabolites of excess niacin, N1-methyl-2-pyridone-5-carboxamide (2PY) and N1-methyl-4-pyridone-3-carboxamide (4PY), were associated with increased 3-year MACE risk in two validation cohorts (US n = 2,331 total, n = 774 females; European n = 832 total, n = 249 females) (adjusted hazard ratio (HR) (95% confidence interval) for 2PY: 1.64 (1.10-2.42) and 2.02 (1.29-3.18), respectively; for 4PY: 1.89 (1.26-2.84) and 1.99 (1.26-3.14), respectively). Phenome-wide association analysis of the genetic variant rs10496731, which was significantly associated with both 2PY and 4PY levels, revealed an association of this variant with levels of soluble vascular adhesion molecule 1 (sVCAM-1). Further meta-analysis confirmed association of rs10496731 with sVCAM-1 (n = 106,000 total, n = 53,075 females, P = 3.6 × 10

Indexed as

Cardiovascular DiseasesNiacinAnimalsFemaleHumansInflammationMiceProportional Hazards ModelsNiacin

Identifiers

PMID38374343
PMCPMC11841810
OpenAlexW4391925517

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.